Citius Pharmaceuticals’ (CTXR) Buy Rating Reiterated at D. Boral Capital
Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $9.00 price target on the stock. Several other equities analysts have also weighed in on CTXR. Maxim Group […]
Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $9.00 price target on the stock. Several other equities analysts have also weighed in on CTXR. Maxim Group […]
